A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease
Information source: UCB
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Parkinson's Disease
Intervention: PARCOPA (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: UCB Official(s) and/or principal investigator(s):
Patricia Witt, Study Director, Affiliation: UCB
Summary
The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa
Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets,
in subjects with stable Parkinson's disease.
Clinical Details
Official title: A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease
Study design: Randomized, Open Label, Dose Comparison, Crossover Assignment
Detailed description:
See approved Package Insert for Adverse Event information.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Stable Parkinson's Disease
Exclusion Criteria:
- Not using carbidopa/levodopa tablets
Locations and Contacts
Schwarz, Milwaukee, Wisconsin, United States
Additional Information
Starting date: January 2004
Ending date: May 2004
Last updated: April 16, 2008
|
